STOCKHOLM, Aug. 18, 2021 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma"), a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux ...

-- Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases -- Claret Capital Partners providing growth funding of up to ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

"The need for new alternatives to PPIs is evident as PCABs are making great progress worldwide," said Christer Ahlberg, CEO of Cinclus Pharma. Financial Summary, July - September 2024 Net sales ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Cinclus Pharma reported quarterly financial results showing a cash position of SEK 540 million at the end of Q3 2025, down from SEK 589 million in Q2. The company generated revenues of SEK 10 million ...

"The past year was marked by significant progress for Cinclus Pharma. Our first Phase III study has had a promising start, and we expect to present topline results during the second half of the year.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

STOCKHOLM, April 16, 2020 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma"), which is developing a novel treatment for gastroesophageal reflux disease, announced today the appointment of ...

London, 13 March, 2026, Claret Capital Partners (‘Claret’), Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28 million in Cinclus Pharma ...

Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases Claret Capital Partners providing growth funding of up to €28M to ...

Also contributes to funding remaining development and pre-launch activities of Cinclus lead asset, linaprazan glurate, toward market approval and commercialisation London, 13 March, 2026, Claret ...